Table 1

Chemotherapy regimen and positive cases detected
Chemotherapy regimen No. of patients No. of MSI-H No. of MSI-L- Recurrence /2ndCA
High conc. FECa 68 19 37 14
5-Floururacil 500 mg/m2
Epirubicin 90–100 mg/m2
Cyclophosphamide 600 mg/m2
Low conc. FECa 31 4 18 2
5-Floururacil 300–400 mg/m2
Epirubicin 50–75 mg/m2
Cyclophosphamide 400 mg/m2
ACb 13 0 6 0
Adriamycin (Doxorubicin) 60 mg/m2
Cyclophosphamide 600 mg/m2
TCc 3 0 2 0
Taxotere (Docetaxel) 75 mg/m2
Cyclophosphamide 600 mg/m2
PTd 2 0 1 0
Carboplatin (Paraplatin) AUC 6 mg/ml/min
Taxotere 175 mg/m2
TAe 1 0 0 0
Taxotere 90 mg/m2
Avastin (Bevacizumab) 10 mg/kg
THf 3 0 0 0
Taxotere 90 mg/m2
Herceptin (Trastuzumab) 4 mg/kg
LTg 1 0 0 0
Lapatinib (Tykerb) 1500 mg po
Taxotere 175 mg/m2
TEh 1 0 0 0
Epirubicin 75 mg/m2
Taxotere 200 mg/m2
Total 123 23 64 16

Abbreviations: a = 5-Floururacil, Epirubicin and Cyclophosphomide, b = Adriamycin and Cyclophosphamide, c = Taxotere and Cyclophosphamide, d = Paraplatin and Taxotere, e = Taxotere and Avastin, f = Taxotere and Herceptin, g = Lapatinib and Taxotere, h = Epirubicin and Taxotere.

Kamat et al.

Kamat et al. BMC Cancer 2012 12:373   doi:10.1186/1471-2407-12-373

Open Data